Boston Scientific sees success in PFA device trial

Results from the Advantage AF study (NCT05443594) found that the company’s pulsed field ablation (PFA) system and the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) devices were able to reduce the rate at which patients living with AF experienced heart flutters and other cardiac events.